Currently, three CDK4/6 inhibitors have been approved in combination with hormonal therapies for the treatment of breast cancer patients, but patients are prone to develop drug resistance with long-term use (Papadimitriou et al., 2022). This evidence concerns the gene CDK4 and breast carcinoma.